Article Text

Download PDFPDF
Preoperative Enoxaparin Is Safe to Use in Major Gynecologic Surgery for Prophylaxis of Venous Thromboembolism: A Retrospective Cohort Study
  1. Martin A. Martino, MD*,
  2. Jennifer G. George, MD,
  3. Christine C. Chen, MD*,
  4. Vijaya Galic, MD, MBA*,,
  5. Rachna Kapoor, MBBS, MPH§,
  6. Kelly C. Murray, MD,
  7. Jocelyn Shubella*,
  8. Eva Riker, MD,
  9. Johnathan M. Lancaster, MD, PhD§ and
  10. Mitchel S. Hoffman, MD
  1. *Department of Obstetrics and Gynecology, Lehigh Valley Health Network, Allentown, PA;
  2. Department of Obstetrics and Gynecology, University of South Florida College of Medicine, Tampa, FL;
  3. Columbia University, New York, NY;
  4. §H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, FL; and
  5. Emory University, Atlanta, GA.
  1. Address correspondence and reprint requests to Martin A. Martino, MD, Division of Gynecologic Oncology, Lehigh Valley Health Network, 1240 S Cedar Crest Blvd Ste. 403, Allentown, PA 18103. E-mail: Martin_A.Martino@lvh.com.

Abstract

Objective To evaluate the safety of preoperative enoxaparin in patients undergoing major gynecologic oncology surgery.

Methods We identified a retrospective cohort group of patients undergoing major gynecologic oncology surgery from June 2002 to June 2004. Exclusion criteria included laparoscopic surgery, inferior vena cava filter, history of venous thromboembolism, and current anticoagulation for prior venous thromboembolism. All patients received prophylaxis with sequential pneumatic compression devices and early ambulation. We identified patients who received (preoperative and postoperative) enoxaparin (20–40 mg) and compared them to patients who received no additional prophylaxis other than pneumatic compression alone. Patient outcomes including estimated blood loss, blood transfusions, operative time, and length of hospital stay were collected. Statistical analysis was performed using the χ2 Wilcoxon rank sum tests. This study was approved by the institutional review board.

Results We identified 122 patients who met our study criteria; there were 63 patients who received preoperative enoxaparin and 59 patients who received no additional prophylaxis. Both groups were similar in age, body mass index, race, comorbidities, cancer diagnosis, and surgical procedure. There was no significant difference between the enoxaparin group and the sequential pneumatic compression devices–only group regarding transfusion rates (29% and 27%; P = 0.86), operating time (150 and 140 minutes; P = 0.16), blood loss greater than 500 cc (35% and 37%; P = 0.79), and length of stay (5 vs 6 days).

Conclusion The use of preoperative enoxaparin is not associated with increased blood loss, transfusion requirements, operative time, or hospital stay among patients having major gynecologic surgery.

  • Enoxaparin
  • Gynecologic Surgery
  • Prophylaxis

Statistics from Altmetric.com

Footnotes

  • None of the authors have any relevant financial or commercial relationships to disclose as defined by the Accreditation Council for Continuing Medical Education’s (ACCME) that relate to the research presented in this article.

  • The authors did not receive financial support for this work.

  • The IRB at the University of South Florida approved this study.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.